Cargando…

Myotilin, a New Topotecan Resistant Protein in Ovarian Cancer Cell Lines

Background: Low effectiveness of chemotherapy in ovarian cancer results from development of drug resistance during treatment. Topotecan (TOP) is a chemotherapeutic drug used in second-line chemotherapy of this cancer. Unfortunately, during treatment cancer can develop diverse cellular and tissue spe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sterzyńska, Karolina, Klejewski, Andrzej, Wojtowicz, Karolina, Świerczewska, Monika, Nowicki, Michał, Brązert, Jacek, Januchowski, Radosław
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277650/ https://www.ncbi.nlm.nih.gov/pubmed/30519347 http://dx.doi.org/10.7150/jca.27342

Ejemplares similares

The Role of Matrix Gla Protein (MGP) Expression in Paclitaxel and Topotecan Resistant Ovarian Cancer Cell Lines
por: Sterzyńska, Karolina, et al.
Publicado: (2018)

New and Old Genes Associated with Primary and Established Responses to Cisplatin and Topotecan Treatment in Ovarian Cancer Cell Lines
por: Świerczewska, Monika, et al.
Publicado: (2017)

Expression of Osteoblast-Specific Factor 2 (OSF-2, Periostin) Is Associated with Drug Resistance in Ovarian Cancer Cell Lines
por: Sterzyńska, Karolina, et al.
Publicado: (2019)

The significance of lumican expression in ovarian cancer drug-resistant cell lines
por: Klejewski, Andrzej, et al.
Publicado: (2017)

Mutual Expression of ALDH1A1, LOX, and Collagens in Ovarian Cancer Cell Lines as Combined CSCs- and ECM-Related Models of Drug Resistance Development
por: Sterzyńska, Karolina, et al.
Publicado: (2018)

Microarray-based detection and expression analysis of new genes associated with drug resistance in ovarian cancer cell lines
por: Januchowski, Radosław, et al.
Publicado: (2017)

Increased Expression of Several Collagen Genes is Associated with Drug Resistance in Ovarian Cancer Cell Lines
por: Januchowski, Radosław, et al.
Publicado: (2016)

Effect of ALDH1A1 Gene Knockout on Drug Resistance in Paclitaxel and Topotecan Resistant Human Ovarian Cancer Cell Lines in 2D and 3D Model
por: Nowacka, Marta, et al.
Publicado: (2022)

Piperine Targets Different Drug Resistance Mechanisms in Human Ovarian Cancer Cell Lines Leading to Increased Sensitivity to Cytotoxic Drugs
por: Wojtowicz, Karolina, et al.
Publicado: (2021)

Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines
por: Januchowski, Radosław, et al.
Publicado: (2016)

New and Old Genes Associated with Primary and Established Responses to Paclitaxel Treatment in Ovarian Cancer Cell Lines
por: Świerczewska, Monika, et al.
Publicado: (2018)

PTPRK Expression Is Downregulated in Drug Resistant Ovarian Cancer Cell Lines, and Especially in ALDH1A1 Positive CSCs-Like Populations
por: Świerczewska, Monika, et al.
Publicado: (2019)

The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Cisplatin- and Paclitaxel-Resistant Ovarian Cancer Cell Lines
por: Kazmierczak, Dominika, et al.
Publicado: (2022)

The Significance of MicroRNAs Expression in Regulation of Extracellular Matrix and Other Drug Resistant Genes in Drug Resistant Ovarian Cancer Cell Lines
por: Kazmierczak, Dominika, et al.
Publicado: (2020)

The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Doxorubicin and Topotecan Resistant Ovarian Cancer Cell Lines
por: Stasiak, Piotr, et al.
Publicado: (2022)

MDR Gene Expression Analysis of Six Drug-Resistant Ovarian Cancer Cell Lines
por: Januchowski, Radosław, et al.
Publicado: (2013)

Extracellular Matrix Proteins Expression Profiling in Chemoresistant Variants of the A2780 Ovarian Cancer Cell Line
por: Januchowski, Radosław, et al.
Publicado: (2014)

Conformational plasticity and evolutionary analysis of the myotilin tandem Ig domains
por: Puž, Vid, et al.
Publicado: (2017)

Molecular basis of F-actin regulation and sarcomere assembly via myotilin
por: Kostan, Julius, et al.
Publicado: (2021)

Prediction of steroid resistance and steroid dependence in nephrotic syndrome children
por: Zaorska, Katarzyna, et al.
Publicado: (2021)

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2023)

RNAi-mediated Gene Silencing of Mutant Myotilin Improves Myopathy in LGMD1A Mice
por: Liu, Jian, et al.
Publicado: (2014)

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
por: Ma, J., et al.
Publicado: (1998)

Maintenance of muscle mass, fiber size, and contractile function in mice lacking the Z-disc protein myotilin
por: Ochala, Julien, et al.
Publicado: (2009)

Indications for a Novel Muscular Dystrophy Pathway: γ-Filamin, the Muscle-Specific Filamin Isoform, Interacts with Myotilin
por: van der Ven, Peter F.M., et al.
Publicado: (2000)

Pharmacological Effect of Quercetin in Hypertension and Its Potential Application in Pregnancy-Induced Hypertension: Review of In Vitro, In Vivo, and Clinical Studies
por: Ożarowski, Marcin, et al.
Publicado: (2018)

Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy
por: Lee, Myung-Won, et al.
Publicado: (2020)

Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines
por: Vanhoefer, U, et al.
Publicado: (1999)

Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer
por: Gore, M, et al.
Publicado: (2001)

Gene Expression Indicates Altered Immune Modulation and Signaling Pathway Activation in Ovarian Cancer Patients Resistant to Topotecan
por: Menyhárt, Otília, et al.
Publicado: (2019)

Commentary: Periocular topotecan for retinoblastoma
por: Sharma, Minal, et al.
Publicado: (2018)

The Impact of Integrin-Mediated Matrix Adhesion on Cisplatin Resistance of W1 Ovarian Cancer Cells
por: Wantoch von Rekowski, Kathleen, et al.
Publicado: (2019)

Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer
por: Levitt, N C, et al.
Publicado: (2005)

Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts.
por: Pratesi, G., et al.
Publicado: (1995)

Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer
por: Poveda, A., et al.
Publicado: (2017)

New 5-Hydroxycoumarin-Based Tyrosyl-DNA Phosphodiesterase I Inhibitors Sensitize Tumor Cell Line to Topotecan
por: Khomenko, Tatyana M., et al.
Publicado: (2023)

Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study
por: Aktas, Gokmen, et al.
Publicado: (2016)

Topotecan and Cyclophosphamide in Adults with Relapsed Sarcoma
por: Blanchette, P., et al.
Publicado: (2012)

Periocular topotecan for vitreous seeds in retinoblastoma
por: Sthapit, Purnima R, et al.
Publicado: (2018)

The Prognostic Value of Cancer Stem Cell Markers (CSCs) Expression—ALDH1A1, CD133, CD44—For Survival and Long-Term Follow-Up of Ovarian Cancer Patients
por: Izycka, Natalia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cppj94g03dgj6dih71c18v2d0e